Claims for Patent: 9,663,826

Summary for Patent: 9,663,826

Title:	System and method of genomic profiling
Abstract:	The present invention relates to a system and method of genomic profiling and is particularly useful in genomic differentiation of heterogeneous and polyclonal neoplastic cell populations, preferably of flow sorted formalin fixed paraffin embedded samples. The present invention includes methods of improving resolution for identifying aberration in variable carcinoma genomes and/or heterogeneous cell populations. The present invention also includes kits configured to improve genomic resolution and the ability to identify genomic aberration in variable and/or heterogeneous cell populations.
Inventor(s):	Barrett; Michael T. (Scottsdale, AZ), Lenkiewicz; Elizabeth (Scottsdale, AZ), Holley; Tara (Phoenix, AZ)
Assignee:	The Translational Genomics Research Institute (Phoenix, AZ)
Application Number:	14/378,650
Patent Claims:	1. A method of identifying aberrations in a variable cancer cell genome sample, comprising: obtaining a cancerous tumor sample comprising normal and abnormal cells; creating a suspension of de-agglomerated nuclei of the cells suitable for flow sorting; sorting the nuclei into a plurality of fractions based at least on a quantification of genetic material in the nuclei; extracting the genetic material from at least a portion of the sorted nuclei; differentially labeling the extracted genetic material and a reference sample; hybridizing the labeled extracted genetic material and reference sample on a feature comparative genomic hybridization array; comparing the labeled extracted genetic material with the labeled reference sample to infer aberrations unique to the labeled extracted genetic material; preparing a fragmented library comprising a whole genome library and/or an exome library from the extracted genetic material; amplifying the fragmented library by generating a plurality of paired-end clusters from a plurality of fragments from the fragmented library; and, determining the sequence of the plurality of fragments through parallel sequencing; wherein an aberration interval in the extracted genetic material is considered similar to an aberration interval in the labeled reference sample when an overlap exceeds about 0.5, wherein the overlap of two aberration intervals comprises the genomic length of their intersection divided by the genomic length of their union. 2. The method of claim 1, wherein the cancerous tumor sample comprises a formalin fixed paraffin embedded (FFPE) cancerous tumor sample. 3. The method of claim 1, wherein the aberrations are detected in the course of a single-patient diagnosis and with the use of an aberration detection algorithm; or the portion of the sorted nuclei from which the genetic material is extracted comprises at least two fractions. 4. The method of claim 3, further comprising inferring genomic tumor evolution based on a comparison between aberrations in the genetic material from the plurality of fractions and treatment history of the patient. 5. The method of claim 1, wherein the cancerous tumor is selected from the group consisting of: breast cancer, large intestinal cancer, lung cancer, small lung cancer, stomach cancer, liver cancer, blood cancer, bone cancer, pancreatic cancer, skin cancer, head or neck cancer, cutaneous or intraocular melanoma, uterine sarcoma, ovarian cancer, rectal or colorectal cancer, anal cancer, colon cancer, fallopian tube carcinoma, endometrial carcinoma, cervical cancer, vulval cancer, vaginal carcinoma, Hodgkin's disease, non-Hodgkin's lymphoma, esophageal cancer, small intestine cancer, endocrine cancer, thyroid cancer, parathyroid cancer, adrenal cancer, chronic or acute leukemia, soft tissue tumor, urethral cancer, penile cancer, prostate cancer, lymphocytic lymphoma, bladder carcinoma, kidney cancer, ureter cancer, renal carcinoma, renal pelvic carcinoma, CNS tumor, primary CNS lymphoma, bone marrow tumor, brain stem nerve gliomas, pituitary adenoma, testicular cancer, oral cancer, pharyngeal cancer and uveal melanoma. 6. The method of claim 5, wherein the cancerous tumor is selected from the group consisting of a prostate adenocarcinoma, a pancreatic adenocarcinoma, a breast carcinoma, a bladder carcinoma, a glioblastoma, an ovarian carcinoma, and a melanoma. 7. The method of claim 1, wherein sorting the nuclei further comprises using a flow cytometer. 8. The method of claim 7, wherein using a flow cytometer comprises using a flow rate of between about 50 and about 1500 events per second; between about 100 and about 1000 events per second; or between about 300 and about 700 events per second. 9. The method of claim 7, wherein using a flow cytometer comprises using a flow stream differential pressure (sheath/sample) of between about 0.1 and about 1.0; between about 0.4 and about 1.0; or between about 0.6 and about 1.0. 10. The method of claim 7, further comprising achieving an acceptable sorting efficiency of at least about 60%; at least about 70%; or at least about 80%. 11. A method of identifying aberrations in a variable cancer cell genome derived from a formalin fixed paraffin embedded (FFPE) cancerous tumor sample, comprising: dewaxing the sample; rehydrating the sample; treating the sample to obtain a suspension of de-agglomerated nuclei suitable for flow sorting; sorting the nuclei into a plurality of fractions based at least on a quantification of genetic material in the nuclei; profiling the ploidy and cell cycle fractions of the nuclei; extracting the genetic material from at least a portion of the sorted nuclei; amplifying the genetic material through single primer isothermal amplification; and, digesting the genetic material to substantial uniformity with an endonuclease; differentially labeling the digested genetic material and a reference sample; hybridizing the labeled digested genetic material and reference sample on a feature comparative genomic hybridization array; comparing, with an aberration detection algorithm, the labeled digested genetic material with the labeled reference sample to infer aberrations unique to the labeled digested genetic material; preparing from the digested genetic material a fragmented library comprising a whole genome library or an exome library from the extracted genetic material; amplifying the fragmented library by generating a plurality of paired-end clusters from a plurality of fragments from the fragmented library; and determining the sequence of the plurality of fragments through parallel sequencing; wherein an aberration interval in the extracted genetic material is considered similar to an aberration interval in the labeled reference sample when an overlap exceeds about 0.5, wherein the overlap of two aberration intervals comprises the genomic length of their intersection divided by the genomic length of their union. 12. The method of claim 11, wherein treating the sample comprises processing the sample with EDTA, collagenase, and hyaluronidase. 13. The method of claim 11, wherein the number of sorted nuclei is at least 50,000. 14. The method of claim 11, further comprising, prior to sorting the nuclei, staining the nuclei with 4',6-diamidino-2-phenylindole and/or wherein the endonuclease is DNAse 1. 15. The method of claim 11, wherein the cancerous tumor is selected from the group consisting of: breast cancer, large intestinal cancer, lung cancer, small lung cancer, stomach cancer, liver cancer, blood cancer, bone cancer, pancreatic cancer, skin cancer, head or neck cancer, cutaneous or intraocular melanoma, uterine sarcoma, ovarian cancer, rectal or colorectal cancer, anal cancer, colon cancer, fallopian tube carcinoma, endometrial carcinoma, cervical cancer, vulval cancer, vaginal carcinoma, Hodgkin's disease, non-Hodgkin's lymphoma, esophageal cancer, small intestine cancer, endocrine cancer, thyroid cancer, parathyroid cancer, adrenal cancer, chronic or acute leukemia, soft tissue tumor, urethral cancer, penile cancer, prostate cancer, lymphocytic lymphoma, bladder carcinoma, kidney cancer, ureter cancer, renal carcinoma, renal pelvic carcinoma, CNS tumor, primary CNS lymphoma, bone marrow tumor, brain stem nerve gliomas, pituitary adenoma, testicular cancer, oral cancer, pharyngeal cancer and uveal melanoma. 16. The method of claim 15, wherein the cancerous tumor is selected from a group consisting of a prostate adenocarcinoma, a pancreatic adenocarcinoma, a breast carcinoma, a bladder carcinoma, a glioblastoma, an ovarian carcinoma, and a melanoma. 17. The method of claim 11, wherein the reference sample is a pooled 46, XX reference sample. 18. The method of claim 11, wherein the array requires a hybridization volume of at least 400 microliters.

Details for Patent 9,663,826

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	05/05/2004		2032-02-15
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	12/02/2004		2032-02-15
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	10/26/2004		2032-02-15
Akorn, Inc.	HYDASE	hyaluronidase	Injection	021716	10/25/2005		2032-02-15
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2032-02-15